▶ 調査レポート

高解像度溶融(HRM)分析のグローバル市場(2023~2028):試薬・消耗品、器具、ソフトウェア・サービス

• 英文タイトル:High-Resolution Melting Analysis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Mordor Intelligenceが調査・発行した産業分析レポートです。高解像度溶融(HRM)分析のグローバル市場(2023~2028):試薬・消耗品、器具、ソフトウェア・サービス / High-Resolution Melting Analysis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028) / MRC2303K086資料のイメージです。• レポートコード:MRC2303K086
• 出版社/出版日:Mordor Intelligence / 2023年2月
• レポート形態:英文、PDF、110ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥712,500 (USD4,750)▷ お問い合わせ
  Corporate License¥1,312,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の調査レポートでは、世界の高解像度溶融(HRM)分析市場規模が、予測期間中、CAGR 3.3%で増大すると予測されています。本レポートでは、高解像度溶融(HRM)分析の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品・サービス別(試薬・消耗品、器具、ソフトウェア・サービス)分析、用途別(SNPジェノタイピング、突然変異発見、病原菌同定、その他)分析、エンドユーザー別(研究所・学術研究機関、製薬・バイオテクノロジー企業、その他)分析、地域別(アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン)分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Thermo Fisher Scientific, Inc.、Bio-Rad Laboratories, Inc.、Qiagen NV、Agilent Technologies, Inc.、Illumina, Inc.、F. Hoffmann-La Roche AG、Azura Genomics、Canon Inc.、bioMérieux SA、Meridian Bioscience Inc.などの企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の高解像度溶融(HRM)分析市場規模:製品・サービス別
- 試薬・消耗の市場規模
- 器具の市場規模
- ソフトウェア・サービスの市場規模
・世界の高解像度溶融(HRM)分析市場規模:用途別
- SNPジェノタイピングにおける市場規模
- 突然変異発見における市場規模
- 病原菌同定における市場規模
- その他用途における市場規模
・世界の高解像度溶融(HRM)分析市場規模:エンドユーザー別
- 研究所・学術研究機関における市場規模
- 製薬・バイオテクノロジー企業における市場規模
- その他エンドユーザーにおける市場規模
・世界の高解像度溶融(HRM)分析市場規模:地域別
- 北米の高解像度溶融(HRM)分析市場規模
アメリカの高解像度溶融(HRM)分析市場規模
カナダの高解像度溶融(HRM)分析市場規模
メキシコの高解像度溶融(HRM)分析市場規模

- ヨーロッパの高解像度溶融(HRM)分析市場規模
ドイツの高解像度溶融(HRM)分析市場規模
イギリスの高解像度溶融(HRM)分析市場規模
フランスの高解像度溶融(HRM)分析市場規模

- アジア太平洋の高解像度溶融(HRM)分析市場規模
中国の高解像度溶融(HRM)分析市場規模
日本の高解像度溶融(HRM)分析市場規模
インドの高解像度溶融(HRM)分析市場規模

- 南米/中東の高解像度溶融(HRM)分析市場規模
南アフリカの高解像度溶融(HRM)分析市場規模
ブラジルの高解像度溶融(HRM)分析市場規模
アルゼンチンの高解像度溶融(HRM)分析市場規模

・競争状況
・市場機会・将来動向

The High-Resolution Melting analysis market is poised to register a CAGR of nearly 3.3% over the forecast period.

The High-Resolution Melting (HRM) analysis is one of the novel techniques that help researchers understand the variations in nucleic acid sequences. Therefore, this technique was widely used during the COVID-19 pandemic. The HRM analysis is used to differentiate the various types of viruses and their composition. The researchers used HRM analysis to discriminate between the SARS-CoV-2 Omicron variants BA.1 and BA.2. Similarly, mutations in the coronavirus were studied with the help of HRM analysis during the pandemic. As per the September 2022 data published by Biochemistry and Biophysics Journal, it was observed that HRM analysis played a key role while differentiating between various strains of the coronavirus. It also contributed largely to understanding the characteristics of the coronavirus and its nuclear composition. Hence, with the effectiveness of HRM analysis, it is believed that the market studied was positively affected during the pandemic. Moreover, even after the pandemic, there is a growing use of HRM analysis which may drive market growth in the post-pandemic era.

The primary factor contributing to the market’s growth is the increase in genetic disorders and infectious diseases. According to the WHO 2021 data, approximately 50,000 people die daily from contagious diseases. 30 new diseases have surfaced in the last 20 years, threatening the health of hundreds of millions of people. The rising burden of infectious diseases globally contributes mainly to market growth. Furthermore, the growing usage of HRM (High-Resolution Melting) in identifying pathogens and the advantages of HRM over other genotyping techniques are boosting the market growth. However, the HRM analysis’s technical limitations are the market growth’s major drawback.

Furthermore, the increasing occurrence of rare genetic diseases is augmenting the demand for novel techniques, such as HRM analysis, to understand the cause of the disease and provide better treatments. The research suggests that around 70% of rare diseases have genetic causes. Data published by Research Centre for Medical Genetics in August 2021 indicates that there were more than 45,000 people across the rural areas of Europe with rare hereditary diseases. Similarly, as per the Orphanet portal of rare diseases, around 10,500 rare diseases are registered worldwide as of 2022. With an increasing rare genetic disease burden, it is expected that the use of HRM analysis will increase, which is believed to propel market growth.

However, technical limitations associated with HRM analysis are expected to hinder market growth to some extent.

High-Resolution Melting Analysis Market Trends

SNP Genotyping Expected to Witness Strong Growth

SNP genotyping is a technique that analyzes genomic sequence variations. These single-base substitutions are typically detected using real-time PCR, microarrays, or next-generation sequencing (NGS) techniques.

Genomics is widening its range of applications in biotechnology and social science. For instance, the genetic diversity of a population or the heterogeneity of an individual for any hereditary condition with a recessive inheritance pattern can be used to predict the health and conservation of the population. This data can also help determine the effects of evolutionary processes and pick up genetic patterns of a specific population, including human and animal life.

Additionally, the increasing prevalence of new infectious, chronic, and other types of diseases will boost the market’s growth. For instance, as per the GLOBOCAN 2020 report that estimated the incidence and mortality of 36 cancers in 185 countries globally, there were an estimated 19.3 million new cases of cancer and about 10 million deaths due to cancer across the world.

Translational research has revolutionized the treatment of different chronic and fatal diseases leading to the rise in demand and acceptance of personalized and precision medicine. These treatment therapies have opened a whole new application area for SNP genotyping as the medicine or therapies are developed per the patient’s genomic structure, which requires the analysis of the patient’s genome sequence first. ​The National Cancer Institute of the United States webcasts a report every year that represents the development of a new and advanced approach for analyzing tumors, which holds the potential to bring precision medicine to a broader range of people. Therefore, with the rising genomics and SNP genotyping methods, HRM analysis is expected to increase in the coming years.

North America Expected to Witness Notable Growth

North America is expected to dominate the overall market throughout the forecast period. The market growth is due to the factors such as the presence of key players, the high prevalence of genetic and infectious diseases in the region, and the established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the factors that drive market growth. The United States has the maximum share in this region due to supportive healthcare policies, the high number of patients, and a developed healthcare market.

The American Cancer Society estimated about 1.9 million new cancer cases to be diagnosed in the United States in 2022. More than 16.9 million people in the United States were living with a history of cancer and were alive as of 2022.​ With the rising number of cancer cases across the country, it is believed that the use of HRM analysis will increase, contributing mainly to market growth.

Various government bodies, such as the National Human Genome Research Institute, United States (NHGRI), have been supporting research related to human genome sequencing while funding research related to the genome’s structure, function, and role in health and diseases. Moreover, these organizations support studies on genome research’s ethical, legal, and social implications (ELSI).​​ Also, the initiation by several general hospitals and other concerned organizations in the area of preventive disease by genomics will complement the market’s growth, as well as newer advances and product launches. For instance, in March 2020, the Massachusetts General Hospital announced the launch of new preventive genomics clinics to assist patients in better understanding, preventing, and predicting diseases using their genetic information.

Therefore, with the increasing focus on genomics, the HRM analysis market is expected to witness substantial growth over the forecast period.

High-Resolution Melting Analysis Market Competitor Analysis

The High-Resolution Melting analysis market is moderately competitive and consists of several major players. Some of the international companies which are present in the market are Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., F. Hoffman-La Roche Ltd, Qiagen NV, Agilent Technologies, Inc., Idaho Technology, Inc., Illumina, Inc., Kapa Biosystems, Azura Genomics, and Canon.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Genetic Disorders and Infectious Diseases
4.2.2 Advantages of HRM over Other Genotyping Technologies
4.2.3 Use of HRM in Pathogen Identification
4.3 Market Restraints
4.3.1 Technical Limitations Associated With HRM
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size – Value in USD Million)
5.1 By Product and Service
5.1.1 Reagents and Consumables
5.1.2 Instruments
5.1.3 Software and Services
5.2 By Application
5.2.1 SNP Genotyping
5.2.2 Mutation Discovery
5.2.3 Pathogen Identification
5.2.4 Other Applications
5.3 By End-user
5.3.1 Research Laboratories and Academic Institutes
5.3.2 Pharmaceutical and Biotechnology Companies
5.3.3 Other End-users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific, Inc.
6.1.2 Bio-Rad Laboratories, Inc.
6.1.3 Qiagen NV
6.1.4 Agilent Technologies, Inc.
6.1.5 Illumina, Inc.
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Azura Genomics
6.1.8 Canon Inc.
6.1.9 bioMérieux SA
6.1.10 Meridian Bioscience Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS